Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Gains from Investment Securities (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Gains from Investment Securities for 12 consecutive years, with $3000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Gains from Investment Securities rose 200.0% year-over-year to $3000.0, compared with a TTM value of $4000.0 through Mar 2024, up 166.67%, and an annual FY2024 reading of $3.6 million, changed N/A over the prior year.
  • Gains from Investment Securities was $3000.0 for Q4 2023 at Karyopharm Therapeutics, up from $1000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $11.7 million in Q1 2019 and bottomed at -$231000.0 in Q2 2021.
  • Average Gains from Investment Securities over 5 years is $1.9 million, with a median of $2000.0 recorded in 2022.
  • The sharpest move saw Gains from Investment Securities surged 436.17% in 2019, then crashed 300.0% in 2023.
  • Year by year, Gains from Investment Securities stood at $11.7 million in 2019, then fell by 3.71% to $11.3 million in 2020, then crashed by 98.43% to $177000.0 in 2021, then tumbled by 101.69% to -$3000.0 in 2022, then skyrocketed by 200.0% to $3000.0 in 2023.
  • Business Quant data shows Gains from Investment Securities for KPTI at $3000.0 in Q4 2023, $1000.0 in Q2 2023, and -$4000.0 in Q1 2023.